Chan John K, Cheung Michael K, Huh Warner K, Osann Kathryn, Husain Amreen, Teng Nelson N, Kapp Daniel S
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford Cancer Center, Stanford, California 94305, USA.
Cancer. 2006 Oct 15;107(8):1823-30. doi: 10.1002/cncr.22185.
The purpose of the current study was to determine the potential therapeutic role of lymphadenectomy in women with endometrioid corpus cancer.
Demographic and clinicopathologic information were obtained from the Surveillance, Epidemiology, and End Results Program between 1988-2001. Data were analyzed using Kaplan-Meier methods and Cox proportional hazards regression.
In all, 12,333 women (median age, 64) underwent surgical staging with lymph node assessment, including 9,009, 1,211, 1,223, and 890 with Stage I-IV disease. Over the time intervals 1988-1992, 1993-1997, and 1998-2001, the percentage of patients undergoing lymph node staging increased from 22.6%, 29.6%, to 40.9% (P < .001). In the intermediate/high-risk patients (Stage IB, Grade 3; Stage IC and II-IV, all grades), a more extensive lymph node resection (1, 2-5, 6-10, 11-20, and >20) was associated with improved 5-year disease-specific survivals across all 5 groups at 75.3%, 81.5%, 84.1%, 85.3%, and 86.8%, respectively (P < .001). For Stage IIIC-IV patients with nodal disease, the extent of node resection significantly improved the survival from 51.0%, 53.0%, 53.0%, 60.0%, to 72.0%, (P < .001). However, no significant benefit of lymph node resection in low-risk patients could be demonstrated (Stage IA, all grades; Stage IB, Grades 1 and 2 disease; P = .23). In multivariate analysis, a more extensive node resection remained a significant prognostic factor for improved survival in intermediate/high-risk patients after adjusting for other factors including age, year of diagnosis, stage, grade, adjuvant radiotherapy, and the presence of positive nodes (P < .001).
The findings of the current study suggest that the extent of lymph node resection improves the survival of women with intermediate/high-risk endometrioid uterine cancer.
本研究的目的是确定淋巴结切除术在子宫内膜样子宫体癌女性患者中的潜在治疗作用。
从监测、流行病学和最终结果计划中获取1988年至2001年间的人口统计学和临床病理信息。使用Kaplan-Meier方法和Cox比例风险回归分析数据。
共有12333名女性(中位年龄64岁)接受了伴有淋巴结评估的手术分期,其中9009例、1211例、1223例和890例分别处于I-IV期疾病。在1988 - 1992年、1993 - 1997年和1998 - 2001年期间,接受淋巴结分期的患者百分比从22.6%、29.6%增加到40.9%(P <.001)。在中/高危患者(IB期,3级;IC期和II-IV期,所有分级)中,更广泛的淋巴结切除(1个、2 - 5个、6 - 10个、11 - 20个和>20个)与所有5组患者的5年疾病特异性生存率提高相关,分别为75.3%、81.5%、84.1%、85.3%和86.8%(P <.001)。对于伴有淋巴结疾病的IIIC-IV期患者,淋巴结切除范围显著提高了生存率,从51.0%、53.0%、53.0%、60.0%提高到72.0%(P <.001)。然而,在低风险患者(IA期,所有分级;IB期,1级和2级疾病)中未显示出淋巴结切除的显著益处(P =.23)。在多变量分析中,在调整了包括年龄、诊断年份、分期、分级、辅助放疗和阳性淋巴结的存在等其他因素后,更广泛的淋巴结切除仍然是中/高危患者生存率提高的显著预后因素(P <.001)。
本研究结果表明,淋巴结切除范围可提高中/高危子宫内膜样子宫癌女性患者的生存率。